BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iacobaeus E, Kadri N, Lefsihane K, Boberg E, Gavin C, Törnqvist Andrén A, Lilja A, Brundin L, Blanc KL. Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis-A Phase I Study. J Clin Med 2019;8:E2102. [PMID: 31810187 DOI: 10.3390/jcm8122102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Merimi M, Lagneaux L, Moussa Agha D, Lewalle P, Meuleman N, Burny A, Fahmi H, Najar M. Mesenchymal Stem/Stromal Cells in Immunity and Disease: A Better Understanding for an Improved Use. J Clin Med 2020;9:E1516. [PMID: 32443461 DOI: 10.3390/jcm9051516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Mallis P, Michalopoulos E, Chatzistamatiou T, Stavropoulos-Giokas C. Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection. World J Stem Cells 2020; 12(8): 731-751 [PMID: 32952855 DOI: 10.4252/wjsc.v12.i8.731] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
3 Samoilova EM, Belopasov VV, Ekusheva EV, Zhang C, Troitskiy AV, Baklaushev VP. Epigenetic Clock and Circadian Rhythms in Stem Cell Aging and Rejuvenation. J Pers Med 2021;11:1050. [PMID: 34834402 DOI: 10.3390/jpm11111050] [Reference Citation Analysis]
4 Andrzejewska A, Dabrowska S, Lukomska B, Janowski M. Mesenchymal Stem Cells for Neurological Disorders. Adv Sci (Weinh) 2021;8:2002944. [PMID: 33854883 DOI: 10.1002/advs.202002944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
5 Hamid HA, Sarmadi VH, Prasad V, Ramasamy R, Miskon A. Electromagnetic field exposure as a plausible approach to enhance the proliferation and differentiation of mesenchymal stem cells in clinically relevant scenarios. J Zhejiang Univ Sci B 2022;23:42-57. [PMID: 35029087 DOI: 10.1631/jzus.B2100443] [Reference Citation Analysis]
6 Baklaushev VP, Samoilova EM, Kalsin VA, Yusubalieva GM. Aging and “rejuvenation” of resident stem cells — a new way to active longevity? Journal of Clinical Practice 2022;13:79-91. [DOI: 10.17816/clinpract104999] [Reference Citation Analysis]
7 Zhou X, Hong Y, Zhang H, Li X. Mesenchymal Stem Cell Senescence and Rejuvenation: Current Status and Challenges. Front Cell Dev Biol 2020;8:364. [PMID: 32582691 DOI: 10.3389/fcell.2020.00364] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
8 Krampera M, Le Blanc K. Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. Cell Stem Cell 2021;28:1708-25. [PMID: 34624232 DOI: 10.1016/j.stem.2021.09.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, Ramo Tello C, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MS; MESEMS investigators. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol 2021;20:917-29. [PMID: 34687636 DOI: 10.1016/S1474-4422(21)00301-X] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Smith JA, Nicaise AM, Ionescu RB, Hamel R, Peruzzotti-Jametti L, Pluchino S. Stem Cell Therapies for Progressive Multiple Sclerosis. Front Cell Dev Biol 2021;9:696434. [PMID: 34307372 DOI: 10.3389/fcell.2021.696434] [Reference Citation Analysis]
11 Willekens B, Wens I, Wouters K, Cras P, Cools N. Safety and immunological proof-of-concept following treatment with tolerance-inducing cell products in patients with autoimmune diseases or receiving organ transplantation: A systematic review and meta-analysis of clinical trials. Autoimmun Rev 2021;20:102873. [PMID: 34119672 DOI: 10.1016/j.autrev.2021.102873] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]